ArticleCytotechnology2025
POM121 induces chemoresistance toward cisplatin in non-small cell lung cancer.
Article in Cytotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pore membrane protein 121 (POM121) is highly expressed in non-small cell lung cancer (NSCLC) and is associated with tumor progression and metastasis. However, its role in NSCLC chemoresistance remains unclear. This study aimed to investigate the effect of POM121 on cisplatin (cis-diamminedichloroplatinum [CDDP]) sensitivity in NSCLC and to elucidate its potential molecular mechanisms. Real-time quantitative polymerase chain reaction and western blotting were used to detect the expression of POM121 in normal bronchial epithelial cells and various NSCLC cell lines (A549, H460, H1299, and H1975). POM121 was silenced in NSCLC cells and cisplatin-resistant A549/CDDP cells. Changes in cell viability, half-maximal inhibitory concentration values, and apoptosis rates were analyzed using Cell Counting Kit-8 and flow cytometry, respectively, and the expression of apoptosis-related proteins was detected using western blotting. POM121 expression was significantly upregulated in NSCLC cells. Silencing of POM121 markedly reduced the resistance of A549, H460, and A549/CDDP cells to cisplatin. Silencing of POM121 significantly induced apoptosis in A549, H460, and A549/CDDP cells and promoted apoptosis in cisplatin-induced A549/CDDP cells, suggesting that POM121 may mediate resistance by regulating apoptotic pathways. POM121 promotes cisplatin resistance in NSCLC; its inhibition could be a potential therapeutic strategy to enhance cisplatin efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.